'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset Read more
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor Read more
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says Read more
